Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TFPI

TFPI

Brief Information

Name:Tissue factor pathway inhibitor
Target Synonym:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
Cat. No. Species Product Description Structure Purity Feature
TFI-H8226 Human Biotinylated Human TFPI Protein, His Tag, ultra sensitivity (primary amine labeling)
TFI-H8226-structure
TFI-H8226-sds
TFI-H5226 Human Human TFPI Protein, His Tag (active enzyme)
TFI-H5226-structure
TFI-H5226-sds

Synonym Name

TFPI,LACI,TFPI1,EPI,TFI

Background

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Befovacimab BAY-109; BAY-1093884 Morphosys Ag, Bayer AG Details
ARC-19499 BAX-499; ARC-19499 Archemix Details
KN-057 KN-057 Phase 2 Clinical Suzhou Alphamab Co Ltd Hemophilia A; Hemophilia B Details
Concizumab NN-7415; mAb-2021; Anti-TFPI; mAbTFPI2021; NNC-172-2021; NNC-0172-2021; NNC-0172-0000-2021 Phase 3 Clinical Novo Nordisk A/S Hemophilia A; Hemophilia B; Hemorrhage Details
Marstacimab PF-6741086; PF-06741086 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Hemophilia A; Hemophilia B; Hemorrhage Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message